tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NKTX Stock Latest News

Nkarta price target lowered to $11 from $12 at Stifel
The FlyNkarta price target lowered to $11 from $12 at Stifel
6d ago
NKTX
Nkarta’s Strategic Management and Financial Strength Justify Buy Rating and $10 Target Price
PremiumRatings
Nkarta’s Strategic Management and Financial Strength Justify Buy Rating and $10 Target Price
6d ago
NKTX
Nkarta Advances NKX019 Program Amid Financial Stability
PremiumCompany Announcements
Nkarta Advances NKX019 Program Amid Financial Stability
6d ago
NKTX
Nkarta reports Q3 EPS (29c), consensus (30c)
PremiumThe Fly
Nkarta reports Q3 EPS (29c), consensus (30c)
7d ago
NKTX
Nkarta’s NKX019 Study: A Promising Step in Autoimmune Disease Treatment
PremiumCompany Announcements
Nkarta’s NKX019 Study: A Promising Step in Autoimmune Disease Treatment
21d ago
NKTX
Nkarta, Inc. Advances CAR NK Cell Therapy Study for Immune-Mediated Diseases
PremiumCompany AnnouncementsNkarta, Inc. Advances CAR NK Cell Therapy Study for Immune-Mediated Diseases
21d ago
NKTX
Nkarta price target lowered to $12 from $14 at Stifel
Premium
The Fly
Nkarta price target lowered to $12 from $14 at Stifel
3M ago
NKTX
Promising Developments in Nkarta’s NKX019 Trials Justify Buy Rating
Premium
Ratings
Promising Developments in Nkarta’s NKX019 Trials Justify Buy Rating
3M ago
NKTX
Nkarta’s Strong Financial Position and Promising Clinical Progress Support Buy Rating
PremiumRatings
Nkarta’s Strong Financial Position and Promising Clinical Progress Support Buy Rating
3M ago
NKTX
Nkarta, Inc. Reports Q2 2025 Financial Results
PremiumCompany Announcements
Nkarta, Inc. Reports Q2 2025 Financial Results
3M ago
NKTX
Strategic Positioning and Financial Stability Bolster Nkarta’s Biotech Prospects
PremiumRatings
Strategic Positioning and Financial Stability Bolster Nkarta’s Biotech Prospects
3M ago
NKTX
Nkarta reports Q2 EPS (31c), consensus (35c)
PremiumThe Fly
Nkarta reports Q2 EPS (31c), consensus (35c)
3M ago
NKTX
Nkarta’s Innovative CAR-NK Cell Therapy Platform Drives Buy Rating
PremiumRatingsNkarta’s Innovative CAR-NK Cell Therapy Platform Drives Buy Rating
4M ago
NKTX
Nkarta price target lowered to $14 from $16 at Mizuho
Premium
The Fly
Nkarta price target lowered to $14 from $16 at Mizuho
5M ago
NKTX
Lyell Immunopharma appoints David Shook as CMO, Mark Meltz as general counsel
Premium
The Fly
Lyell Immunopharma appoints David Shook as CMO, Mark Meltz as general counsel
5M ago
LYEL
NKTX
Nkarta Announces Leadership Change with New CMO
PremiumCompany Announcements
Nkarta Announces Leadership Change with New CMO
5M ago
8K
NKTX
Nkarta appoints Shawn Rose as CMO, head of R&D
PremiumThe Fly
Nkarta appoints Shawn Rose as CMO, head of R&D
5M ago
NKTX
Nkarta’s Strategic Enhancements in NKX019 Program and Trial Expansion Drive Positive Buy Rating
PremiumRatings
Nkarta’s Strategic Enhancements in NKX019 Program and Trial Expansion Drive Positive Buy Rating
6M ago
NKTX
Nkarta, Inc. Reports Q1 2025 Financial Results
PremiumCompany Announcements
Nkarta, Inc. Reports Q1 2025 Financial Results
6M ago
NKTX
Nkarta downgraded to Market Perform from Outperform at William Blair
PremiumThe FlyNkarta downgraded to Market Perform from Outperform at William Blair
6M ago
NKTX
Nkarta reports Q1 EPS (43c), consensus (45c)
Premium
The Fly
Nkarta reports Q1 EPS (43c), consensus (45c)
6M ago
NKTX
Nkarta’s Strategic Workforce Reduction and Clinical Progress Justify Buy Rating
Premium
Ratings
Nkarta’s Strategic Workforce Reduction and Clinical Progress Justify Buy Rating
8M ago
NKTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >